The first trial of adjuvant platinum-based chemotherapy plus paclitaxel in patients with high-risk penile cancer provided some insights.

CHICAGO -- A neoadjuvant chemotherapy regimen of cisplatin (Platinol), nab-paclitaxel (Abraxane), capecitabine (Xeloda), and ...

The addition of low-intensity electric tumor treating fields (TTFields) therapy to first-line standard chemotherapy was ...

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...

Here is a recap of every FDA approval announced by the regulatory agency in the month of May, spanning various cancer types.

1 “Globally, penile cancer is rare. However ... higher GI toxicities and hematological toxicities with the 5-FU arm, more neuropathy and liver dysfunction with paclitaxel, similar results in EORTC and ...

Bio-Path expects to utilize an advisory panel of AML experts to assist in the design of the final clinical development plans through potential FDA approval. Other significant milestones expected ...

Liver cancer is a lethal disease with limited treatment options for advanced stages. While risk factors such as viral ...

Modern unhealthy lifestyles and dietary habits have led to a yearly increase in the incidence of metabolism-related liver ...

Relacorilant combined with nab-paclitaxel (Abraxane) significantly improved progression-free and overall survival in patients with platinum-resistant ovarian cancer in the phase 3 ROSELLA trial, ...